Dr. Borghaei Discusses the Results of CheckMate-227 in NSCLC

Hossein Borghaei, DO, MS
Published: Thursday, Jun 14, 2018



Hossein Borghaei, DO, MS, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses the results of the CheckMate-227 trial in non–small cell lung cancer (NSCLC).

CheckMate-227 is a phase III study of nivolumab (Opdivo) plus platinum-doublet chemotherapy versus chemotherapy as a first-line treatment for patients with advanced NSCLC who have <1% PD-L1 tumor expression. Results showed that the addition of nivolumab to chemotherapy did improve progression-free survival in this population, but the responses were not durable. Borghaei says that durability of response is something that has been seen in other immunotherapy-based studies, and is a factor that investigators believe is important in determining the activity of the drug.

Tumor mutational burden (TMB) is a biomarker that has been studied in patients with NSCLC. Particularly, patients with high TMB have demonstrated a greater benefit with nivolumab plus ipilimumab (Yervoy), as well as nivolumab plus chemotherapy. Borghaei says that TMB may be a good way to select patients with NSCLC for treatment with immunotherapy agents.


Hossein Borghaei, DO, MS, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses the results of the CheckMate-227 trial in non–small cell lung cancer (NSCLC).

CheckMate-227 is a phase III study of nivolumab (Opdivo) plus platinum-doublet chemotherapy versus chemotherapy as a first-line treatment for patients with advanced NSCLC who have <1% PD-L1 tumor expression. Results showed that the addition of nivolumab to chemotherapy did improve progression-free survival in this population, but the responses were not durable. Borghaei says that durability of response is something that has been seen in other immunotherapy-based studies, and is a factor that investigators believe is important in determining the activity of the drug.

Tumor mutational burden (TMB) is a biomarker that has been studied in patients with NSCLC. Particularly, patients with high TMB have demonstrated a greater benefit with nivolumab plus ipilimumab (Yervoy), as well as nivolumab plus chemotherapy. Borghaei says that TMB may be a good way to select patients with NSCLC for treatment with immunotherapy agents.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x